Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Relay Medical and Fio Corporation Launch Mobile COVID-19 Testing and Tracking Platform
Relay Medical and Fio Corporation Launch Mobile COVID-19 Testing and Tracking Platform

 

-          Fionet is a first-of-its-kind mobile testing platform for organizations to manage and track on-site COVID-19 testing

-          Fionet Devices, usable by non-expert personnel,

FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test

EnWave unterzeichnet Technologieevaluierungs- und Lizenzoptionsvertrag mit führendem europäischen Snack-Unternehmen
EnWave Signs Technology Evaluation and License Option Agreement with Leading European Snack Company
EnWave Signs Technology Evaluation and License Option Agreement with Leading European Snack Company

Vancouver, B.C., August 26th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced

IMV to Participate at Four Upcoming Investor Conferences
IMV to Participate at Four Upcoming Investor Conferences


IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious

EnWave Corporation Refining Development of a Medical Device to Relieve COVID-19 Symptoms
EnWave Corporation Refining Development of a Medical Device to Relieve COVID-19 Symptoms

 

Vancouver, B.C., August 25, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced

EnWave Corporation Verfeinerungsentwicklung eines medizinischen Geräts zur Linderung der COVID-19-Symptome
EnWave Corporation Verfeinerungsentwicklung eines medizinischen Geräts zur Linderung der COVID-19-Symptome

 

Vancouver, B.C., 25. August 2020, Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab

Dow Jones-Index: Amgen, Honeywell und Salesforce.com kommen!
Dow Jones-Index: Amgen, Honeywell und Salesforce.com kommen!

Wie in der Nacht von Montag auf Dienstag bekannt wurde, kommt es beim Dow Jones-Index zur größten Anpassung seit sieben Jahren. Neu aufgenommen in den US-Leitindex werden dabei die Papiere von Amgen

Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting


Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during

Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results


Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The

Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference
Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference


Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced

QIAGEN führt einfach zu bedienenden, digitalen Test zum Nachweis von SARS-CoV-2-Antikörpern nach beantragter FDA-Notfallzulassung auf dem US-Markt ein
QIAGEN führt einfach zu bedienenden, digitalen Test zum Nachweis von SARS-CoV-2-Antikörpern nach beantragter FDA-Notfallzulassung auf dem US-Markt ein


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung seines neuen Access Anti-SARS-CoV-2 Total Tests auf dem US-Markt bekannt. Hierbei handelt es sich um einen einfach

QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization
QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that

QIAGEN announces new Chairman of Supervisory Board
QIAGEN announces new Chairman of Supervisory Board


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and

QIAGEN gibt neuen Aufsichtsratsvorsitzenden bekannt
QIAGEN gibt neuen Aufsichtsratsvorsitzenden bekannt


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute im Anschluss an eine außerordentliche Sitzung des Aufsichtsrats und des Vorstands einen Wechsel im Vorsitz des Aufsichtsrats

Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against

Antibe Therapeutics Announces Results of Annual and Special Meeting
Antibe Therapeutics Announces Results of Annual and Special Meeting


Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information

EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update
EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update

Vancouver, B.C., August 20th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), a global

EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt  Update zu NutraDried
EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried

Vancouver, B.C., 20. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), ein

Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume

Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!

Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta

True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab
True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab

Vernon (British Columbia), 19. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) (True Leaf) gibt heute bekannt, dass True Leaf Pet Inc. (TLP“) im Rahmen des

True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.
True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.

Vernon, BC - August 19, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (True Leaf) announced today that, as part of the sales process approved by Order of the British

Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology
Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology

August 19, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) are pleased to announce the establishment of a joint

Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode
Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode

19. August 2018 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, die Gründung eines Joint Ventures („J